Request Call Back

Contact Us

Progressive Multifocal Leukoencephalopathy
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



If you believe PML is due to an Multiple Sclerosis drug, please list drug:

   * Please describe your case:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


PML Disease Injury Lawsuits

PML, Progressive Multifocal Leukoencephalopathy | Lawsuits, Lawyers | Disease: Injury, Infection | Side Effects, Prescription Drugs, Medications Avonex, Tysabri

Progressive Multifocal Leukoencephalopathy (PML) is an irregular disorder of the nervous system that mainly affects individuals with suppressed immune systems (including, allograft recipients such as kidney transplant patients; patients with cancers such as leukemia or lymphoma; and approximately 10% of patients with acquired immune deficiency syndrome (AIDS).

The disorder, which is caused by a frequent human polyomavirus, JC virus, is characterized by demyelination or destruction of the myelin sheath that covers nerve cells. The myelin sheath is the fatty covering, which acts as an insulator on nerve fibers in the brain.

Some prescription medications that treat Multiple Sclerosis have been found to cause Progressive Multifocal Leukoencephalopathy (PML). There have been reports of people suffering PML (Progressive Multifocal Leukoencephalopathy), while taking Avonex and Tysabri.

In many circumstances both Avonex and Tysabri are taken together by those who suffer from multiple sclerosis. Tysabri was withdrawn from the market after 2 recent reports of serious side effects among patients who used it along with Avonex. In one instance, the person died, while in another, the person developed a suspected case of progressive multifocal leukoencephalopathy, a rare and frequently fatal disease of the central nervous system.

PML often results in irreversible neurological deterioration and death. Both patients had taken Avonex for more than two years in combination with Tysabri, the two drugs manufacturers said. Other symptoms of PML consist of mental deterioration, vision loss, paralysis, speech disturbances, ataxia (inability to coordinate movements), and comas. In rare cases, seizures can happen. The worst side effect includes death, which occurs for the most part between 1 and 4 months after onset. But, in some circumstances, survival lasts months to years.

Progressive in PML means that it continues to get worse and often leads to serious brain damage. Multifocal means that the JC virus causes disease in several different parts of the brain. Leukoencephalopathy indicates that the disease affects the white matter of the brain. More specifically, the JC virus infects cells in the brain called oligodentrocytes. These cells are responsible for producing myelin, a fatty substance that helps protect nerves in the brain. When too much myelin is lost and not replaced by oligodentrocytes, the nerves become damaged and over time stop working properly.

Legal Help For Victims Affected By PML

If you or a loved one has taken prescription medications that treat Multiple Sclerosis and were diagnosed with Progressive Multifocal Leukoencephalopathy (PML), please fill out the form at the right for a free case evaluation by a qualified defective drug attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).


Rituxan - PML Link Could Spark FDA Action

Jun 1, 2009 | Parker Waichman LLP
U.S Health Regulators are Taking a Look at the Lymphoma U.S. health regulators are taking a look at the lymphoma drug Rituxan because of its possible association with progressive multifocal leukoencephalitis (PML), an often fatal brain infection.  According to The Wall Street Journal, the Food & Drug Administration (FDA) is trying to determine if  patients should take Rituxan for shorter periods, or take breaks from therapy to lessen the risk that they will develop...

Raptiva Gets Black Box Warning for PML, Other Opportunistic Infections

Oct 17, 2008 | Parker Waichman LLP
Labeling of the Psoriasis Drug Raptiva Will Now Bear a New Black Box Warning The labeling  of the psoriasis drug Raptiva will now bear a new black box warning about its association with the deadly brain disease progressive multifocal leukoencephalopathy, or PML, and other life threatening infections.  The Food & Drug Administration (FDA) ordered the black box  after receiving reports of serious infections - including at least one case of PML -  in some patients...

Raptiva Added to List of Drugs Linked to Deadly Brain Disease

Oct 6, 2008 | Parker Waichman LLPp
Raptiva, Genentech Inc’s psoriasis drug, may be linked to a deadly brain disease called progressive multifocal leukoencephalopathy, or PML.  The company sent a letter to healthcare providers last week warning that one Raptiva patient had been diagnosed with the disease, while another had died of unknown causes after developing neurological symptoms.Raptiva is an injectable drug that was approved by the Food & Drug Administration (FDA) in 2003 to treat moderate to severe plaque...

Biotech firms' drug is linked to deaths

Dec 19, 2006 | Los Angeles Times
The Bestselling Medicine for Two of the Country's Biggest Biotech Drug Companies The bestselling medicine for two of the country's biggest biotech drug companies has been further linked to a rare and deadly brain infection, U.S. health officials warned Monday. The news could hurt efforts by Genentech Inc. and Biogen Idec Inc. to expand approved treatments for Rituxan. Patients taking Rituxan, a drug approved to treat rheumatoid arthritis and non-Hodgkins lymphoma, have been known to...

Biogen, Genentech issue warning for Rituxan

Dec 19, 2006 |
Biogen Idec and Genetech Have Issued A Warning to Healthcare Biogen Idec and Genentech have issued a warning to healthcare providers for their oncology drug Rituxan, advising them that the drug has been linked to the deaths of two lupus patients from a rare brain disease. According to an advisory sent out by the Food and Drug Administration early Tuesday, Biogen  and Genentech have sent a letter to healthcare providers informing them that two lupus patients taking Rituxan died of the...

More PML News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo